Similar articles

• A new trifluorinated quinolone: Ro 23-6240 (AM 833).

  Weidekamm E, Stöckel K, Dell D. Weidekamm E, et al. Drugs Exp Clin Res. 1987;13(2):85-90. Drugs Exp Clin Res. 1987. PMID: 3107959
• Quinolone pharmacokinetics and metabolism.

  Lode H, Höffken G, Boeckk M, Deppermann N, Borner K, Koeppe P. Lode H, et al. J Antimicrob Chemother. 1990 Oct;26 Suppl B:41-9. doi: 10.1093/jac/26.suppl_b.41. J Antimicrob Chemother. 1990. PMID: 2124212
• Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.

  Weidekamm E, Portmann R, Suter K, Partos C, Dell D, Lücker PW. Weidekamm E, et al. Antimicrob Agents Chemother. 1987 Dec;31(12):1909-14. doi: 10.1128/AAC.31.12.1909. Antimicrob Agents Chemother. 1987. PMID: 3125788 Free PMC article. Clinical Trial.
• Overview of the pharmacokinetics of fleroxacin.

  Nightingale CH. Nightingale CH. Am J Med. 1993 Mar 22;94(3A):38S-43S. Am J Med. 1993. PMID: 8452184 Review.
• Pharmacokinetics of quinolones in renal insufficiency.

  Fillastre JP, Leroy A, Moulin B, Dhib M, Borsa-Lebas F, Humbert G. Fillastre JP, et al. J Antimicrob Chemother. 1990 Oct;26 Suppl B:51-60. doi: 10.1093/jac/26.suppl_b.51. J Antimicrob Chemother. 1990. PMID: 2124213 Review.